Clexio Biosciences is a clinical-stage pharmaceutical company developing CNS therapies designed to address patients unmet needs through a scientifically based fusion of drugs and innovative technologies. Clexios growing pipeline is focused on the development of safe and effective treatments with rapid onset of action for a wide range of neurological and psychiatric conditions, including major depressive disorder, Parkinsons disease, pain, and other conditions involving impairment of the neurological system.